Treats Manic and Mixed Episodes associated with Bipolar I Disorder Irritability…. ANDA 216208, held by Aurobindo Pharma. Aripiprazole.
As of Nov 16, 2026, ANDA 216208 (Aripiprazole), held by Aurobindo Pharma, was first approved by FDA on Feb 18, 2026, with 0 approved supplements and 0 published complete response letters.
Aripiprazole orally disintegrating tablets are indicated for the treatment of: Schizophrenia Acute Treatment of Manic and Mixed Episodes associated with Bipolar I Disorder Irritability Associated with Autistic Disorder Treatment of Tourette’s Disorder Aripiprazole is an atypical antipsychotic. The oral formulation is indicated for: Schizophrenia Acute Treatment of Manic and Mixed Episodes associated with Bipolar I Irritability Associated with Autistic Disorder Treatment of Tourette's disorder
| Date | Submission | Status | Documents |
|---|---|---|---|
| Feb 18, 2026 | Original application | Approved | None posted |
| Aripiprazole10MG · tablet, orally disintegrating;oral | Aripiprazole | Discontinued |
| Aripiprazole15MG · tablet, orally disintegrating;oral | Aripiprazole | Discontinued |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters